Supraventricular arrhythmia in acute myocardial infarction
Authors:
P. Sedloň
Authors place of work:
Kardiologické oddělení, Interní klinika, 1. LF UK a ÚVN Praha
Published in the journal:
Kardiol Rev Int Med 2010, 12(Supplementum): 17-21
Summary
Supraventricular arrhythmias complicating acute myocardial infarction are a common and usually clinically important problem. The occurrence of certain supraventricular arrhythmias has a significant impact on short- and long-term patient prognosis. Atrial fibrillation is one of the most frequently seen arrhythmias in acute myocardial infarction patients. Especially a new-onset atrial fibrillation a predictor of poorer hospitalization outcome and has an independent and meaningful impact on the future patient prognosis. Long-term effect of antiarrhythmic therapy remains unknown; this therapy is usually indicated only when arrhythmia is associated with severe symptoms or deterioration of the patient’s clinical status. Correction of the risk factors such as hypokalemia, hypoxemia or heart failure is a prerequisite for favourable therapy outcome; amiodaron is widely considered as the first choice antiarhythmic therapy. Early reperfusion therapy reduces the incidence of new-onset atrial fibrillation, most frequently used in the Czech Republic is the primary PCI. Prevention of tromboembolic complications is an essential part of atrial fibrillation treatment. Other supraventricular arrhythmias described in the context of AMI include paroxysmal atrial tachycardia and, rarely, non-paroxysmal atrial tachycardia or multifocal atrial tachycardia. Long-term effect of these arrhythmias on patient prognosis has not been established yet; their onset during AMI could lead to haemodynamic instability and/or worsening of heart failure or myocardial ischemia symptoms. Indication and treatment strategy should be considered individually. Similarly to atrial fibrillation, amiodaron is the first choice antiarrhythmic treatment, if indicated. Thrombembolic event prevention is only rarely needed.
Keywords:
acute coronary syndrome – acute myocardial infarction – supraventricular arrhythmia – atrial fibrillation – prognosis – therapy
Zdroje
1. Thygesen K, Alpert JS, White HD. Joint ESC/ ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J 2007; 28: 2525–2538.
2. Liberthson RR, Salisbury KW, Hutter AM jr et al. Atrial tachyarrhythmias in acute myocardial infarction. Am J Med 1976; 60: 956–960.
3. Schmitt J, Duray G, Gersch BJ et al. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J 2009: 1038–1045.
4. Kyriakidis M, Barbetseas J, Antonopoulos A et al. Early atrial arrhythmias in acute myocardial infarction. Role of the sinus node artery. Chest 1992; 101: 944–947.
5. Flugelman MY, Hasin Y, Shefer A et al. Atrial fibrillation in acute myocardial infarction. Isr J Med Sci 1986; 22: 355–359.
6. Pizzetti F, Turazza FM, Franzosi MG et al. Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. Heart 2001; 86: 527–532.
7. Schmitt J, Duray G, Gersh BJ et al. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J 2009; 30: 1038–1045.
8. Crenshaw BS, Ward SR, Granger CB et al. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol 1997; 30: 406–413.
9. Møller JE, Dahlström U, Gøtzsche O et al. Effects of losartan and captopril on left ventricular systolic and diastolic function after acute myocardial infarction: results of the Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan (OPTIMAAL) echocardiographic substudy. Am Heart J 2004; 147: 494–501.
10. Lehto M, Snapinn S, Dickstein K et al. OPTIMAAL investigators. Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience. Eur Heart J 2005; 26: 350–356.
11. Eldar M, Canetti M, Rotstein Z et al. Significance of paroxysmal atrial fibrillation complicating acute myocardial infarction in the thrombolytic era. SPRINT and Thrombolytic Survey Groups. Circulation 1998; 97: 965–970.
12. Laurent G, Dentan G, Moreau D et al. Atrial fibrillation during myocardial infarction with and without ST segment elevation. Arch Mal Coeur Vaiss 2005; 98: 608–614.
13. Heilbron B, Klein GJ, Talajic M et al. Management of atrial fibrillation in the emergency department and following acute myocardial infarction. Can J Cardiol 2005; 21 Suppl B: 61B–6B.
14. Ramani G, Zahid M, Good CB et al. Comparison of frequency of new-onset atrial fibrillation or flutter in patients on statins versus not on statins presenting with suspected acute coronary syndrome. Am J Cardiol 2007; 100: 404–405.
15. McMurray J, Køber L, Robertson M et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 2005; 45: 525–530.
16. Cappato R. Atrial fibrillation complicating acute myocardial infarction: how should it be interpreted and how should it be treated and prevented? Eur Heart J 2009; 30: 1035–1037.
17. Kontoyannis DA, Anastasiou-Nana MI, Kontoyannis SA et al. Intravenous amiodarone decreases the duration of atrial fibrillation associated with acute myocardial infarction. Cardiovasc Drugs Ther 2001; 15: 155–160.
18. Køber L, Torp-Pedersen C, Gadsbøll N et al. Is digoxin an independent risk factor for long-term mortality after acute myocardial infarction? Eur Heart J 1994; 15: 382–388.
19. Fuster V, Rydén LE, Cannom DS et al. ACC/AHA/ ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006; 8: 651–745.
20. Gorelick PB. Combining aspirin with oral anticoagulant therapy: is this a safe and effective practice in patients with atrial fibrillation? Stroke 2007; 38: 1652–1654.
21. Lip GY, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb Res 2006; 118: 321–333.
22. Manzano-Fernandéz S, Pastor FJ, Marín F et al. Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting. Chest 2008; 134: 559–567.
23. Vojacek J. The results of the RE-LY study promise more effective, safer and easier prevention of embolic complications in patients with non-valvular atrial fibrillation. Vnitr Lek 2009; 55: 1085–1088.
24. Lip GY, Karpha M. Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: the need for consensus and a management guideline. Chest 2006; 130: 1823–1827.
25. Yangni N’Da’O, Brembilla-Perrot B. Clinical characteristics and management of paroxysmal junctional tachycardia in the elderly. Arch Cardiovasc Dis 2008; 101: 143–148.
Štítky
Paediatric cardiology Internal medicine Cardiac surgery CardiologyČlánok vyšiel v časopise
Cardiology Review
2010 Číslo Supplementum
Najčítanejšie v tomto čísle
- Bradycardia in acute myocardial infarction
- Cardiopulmonary resuscitation: annotated ERC Guidelines 2005
- Supraventricular arrhythmia in acute myocardial infarction
- Sudden cardiac death prevention in acute myocardial infarction